Renaissance Technologies’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-283,700
Closed -$19.3M 4584
2022
Q3
$19.3M Buy
+283,700
New +$15.6M 0.03% 691
2022
Q1
Sell
-8,935
Closed -$262K 4614
2021
Q4
$262K Sell
8,935
-76,426
-90% -$2.37M ﹤0.01% 3404
2021
Q3
$2.17M Buy
85,361
+34,681
+68% +$1.02M ﹤0.01% 2026
2021
Q2
$1.77M Buy
+50,680
New +$1.98M ﹤0.01% 2335
2020
Q3
Sell
-50,400
Closed -$3.18M 3800
2020
Q2
$3.18M Buy
50,400
+42,300
+522% +$2.9M ﹤0.01% 1905
2020
Q1
$414K Buy
+8,100
New +$543K ﹤0.01% 2850
2018
Q3
Sell
-217,700
Closed -$9.84M 3637
2018
Q2
$9.84M Sell
217,700
-394,100
-64% -$17.9M 0.01% 1362
2018
Q1
$29.6M Buy
+611,800
New +$34.1M 0.03% 707
2017
Q4
Sell
-186,400
Closed -$5.79M 3556
2017
Q3
$5.79M Buy
+186,400
New +$5.24M 0.01% 1679
2016
Q4
Sell
-101,200
Closed -$2.33M 3541
2016
Q3
$2.33M Buy
+101,200
New +$1.93M ﹤0.01% 2097

Other funds holding GBT

Renaissance Technologies's GBT Position: Q4 2022 in Review

Renaissance Technologies sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 283,700 shares — an estimated $19.3M sold.

Renaissance Technologies first reported a position in GBT in Q3 2016 and held it in 10 quarters. The position peaked at $29.6M in Q1 2018. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Renaissance Technologies reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Renaissance Technologies sold 283,700 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $19.3M.
  • Renaissance Technologies first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 10 quarters.
  • Renaissance Technologies's Global Blood Therapeutics, Inc. position peaked at $29.6M in Q1 2018.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.